0000950103-23-000404.txt : 20230112 0000950103-23-000404.hdr.sgml : 20230112 20230111190133 ACCESSION NUMBER: 0000950103-23-000404 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230111 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230112 DATE AS OF CHANGE: 20230111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRECIGEN, INC. CENTRAL INDEX KEY: 0001356090 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36042 FILM NUMBER: 23524579 BUSINESS ADDRESS: STREET 1: 20374 SENECA MEADOWS PARKWAY CITY: GERMANTOWN STATE: MD ZIP: 20876 BUSINESS PHONE: 301-556-9900 MAIL ADDRESS: STREET 1: 20374 SENECA MEADOWS PARKWAY CITY: GERMANTOWN STATE: MD ZIP: 20876 FORMER COMPANY: FORMER CONFORMED NAME: INTREXON CORP DATE OF NAME CHANGE: 20060313 8-K 1 dp186955_8k.htm FORM 8-K
0001356090 false NASDAQ 0001356090 2023-01-11 2023-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 11, 2023

 

PRECIGEN, INC.

(Exact name of registrant as specified in its charter)

 

Virginia   001-36042   26-0084895

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

20374 Seneca Meadows Parkway, Germantown, Maryland 20876

(Address of principal executive offices) (Zip Code)

 

(301) 556-9900

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, No Par Value   PGEN   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01Regulation FD Disclosure.

 

On January 11, 2023, Precigen, Inc. (the “Company”) issued a press release providing an overview of certain research and development and corporate updates that the Company presented at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. A copy of the press release is attached hereto as Exhibit 99.1.

 

This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

  Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit 99.1 Press Release issued by Precigen, Inc., dated January 11, 2023.
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Precigen, Inc.
     
  By:   /s/ Donald P. Lehr
      Donald P. Lehr
      Chief Legal Officer

 

Dated: January 11, 2023

 

 

 EX-101.SCH 2 pgen-20230111.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 pgen-20230111_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 pgen-20230111_pre.xml XBRL PRESENTATION FILE EX-99.1 5 dp186955_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

 

– Company achieved significant progress for its clinical pipeline in 2022 –

– Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ immunotherapy in recurrent respiratory papillomatosis (RRP) –

 

GERMANTOWN, MD, January 11, 2023 – Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2022 achievements and set forth Precigen's goals for 2023. 

 

"Precigen continued to make significant clinical progress for our UltraCAR-T and AdenoVerse programs in 2022 and we were able to meet or exceed substantially all of the clinical goals we outlined at the J.P. Morgan Healthcare Conference last year. For example, the PRGN-2012 study in RRP continues to accelerate at a rapid pace and we look forward to hosting an R&D update call on January 24th to share safety and efficacy data from the Phase 1 dose escalation and expansion cohorts," said Helen Sabzevari, PhD, President and CEO of Precigen. "In 2023, we will continue to advance our clinical programs with a focus on a rapid path to licensure for programs addressing high unmet patient need."

 

PRGN-2012 AdenoVerse™ Immunotherapy in RRP

 

·Overview: PRGN-2012 is an investigational off-the-shelf (OTS) AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with HPV 6 or HPV 11 for treatment of RRP. PRGN-2012 is currently under evaluation in a Phase 2 clinical trial (clinical trial identifier: NCT04724980). The clinical trial evaluates PRGN-2012 as an adjuvant immunotherapy following standard-of-care surgical removal of visible papillomas in adult patients with RRP. PRGN-2012 has been granted Orphan Drug Designation in patients with RRP by the US Food and Drug Administration (FDA). 

 

·Program Status: Enrollment (N=15) was completed in the Phase 1 study. Precigen initiated dosing in the Phase 2 trial and is rapidly enrolling patients, with 20 patients enrolled to date. The Company will host a virtual R&D event on January 24, 2023 to showcase complete clinical trial data from the Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse Immunotherapy in RRP. The event will be led by Clint T. Allen, MD, Senior Investigator, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute (NCI) and lead associate investigator for the PRGN-2012 clinical trial and Helen Sabzevari, PhD, President and CEO of Precigen. The Company plans to outline the regulatory strategy for PRGN-2012 in 2023 based on discussions with the FDA.

 

PRGN-2009 AdenoVerse™ Immunotherapy in HPV-associated Cancers

 

·Overview: PRGN-2009 is an OTS investigational immunotherapy utilizing the AdenoVerse platform designed to activate the immune system to recognize and target HPV-positive (HPV+) solid tumors. PRGN-2009 is currently under evaluation in a Phase 1/2 clinical trial (clinical trial identifier: NCT04432597). The Phase 1 trial is evaluating safety and response of PRGN-2009 as a monotherapy (Arm A) and in combination with M7824 (Arm B) in previously treated patients with recurrent or metastatic HPV-associated cancers. 

 

·Program Status: Enrollment was completed in the Phase 1 monotherapy (N=6) and combination therapy (N=11) arms in patients with recurrent or metastatic HPV-associated cancers and patient follow up is ongoing. The Company expects Phase 1 monotherapy and combination therapy safety and efficacy data to be presented in the first half of 2023. Enrollment is nearing completion in the Phase 2 monotherapy arm in newly diagnosed oropharyngeal squamous cell carcinoma (OPSCC) patients with 19 of 20 estimated patients enrolled as of the end of 2022. Interim clinical data presentation from the Phase 2 monotherapy arm is expected in the second half of 2023.

 

 

 

PRGN-3006 UltraCAR-T® in Acute Myeloid Leukemia (AML)

 

·Overview: PRGN-3006 is an investigational multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to simultaneously express a CAR specifically targeting CD33, membrane bound IL-15 (mbIL15), and a kill switch. PRGN-3006 UltraCAR-T is under evaluation in a Phase 1b clinical trial (clinical trial identifier: NCT03927261) for the treatment of patients with relapsed or refractory AML or higher-risk myelodysplastic syndromes (MDS). PRGN-3006 UltraCAR-T has been granted Orphan Drug Designation in patients with AML and Fast Track Designation in patients with relapsed/refractory AML by the FDA. 

 

·Program Status: Enrollment was completed in the Phase 1 dose escalation cohorts of the study. Precigen presented positive Phase 1 dose escalation data for autologous PRGN-3006 UltraCAR-T® manufactured overnight for next day infusion in relapsed or refractory AML patients at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The Phase 1b dose expansion study of PRGN-3006 UltraCAR-T was expanded to Mayo Clinic in Rochester, Minnesota, enhancing the decentralized manufacturing model. The first patient was successfully dosed at the expansion site with PRGN-3006 UltraCAR-T. Site activation activities are in progress at several additional major cancer centers across the US as part of the multicenter expansion of the study. The Company received FDA clearance to incorporate repeat dosing in the Phase 1b expansion phase of the study, at the discretion of the treating physician. Phase 1b clinical trial data presentation is expected in 2024.

 

PRGN-3005 UltraCAR-T® in Ovarian Cancer

 

·Overview: PRGN-3005 UltraCAR-T is an investigational multigenic, autologous CAR-T cell therapy engineered to express a CAR specifically targeting the unshed portion of MUC16, which is highly expressed on ovarian tumors with limited normal tissue expression, mbIL15, and a kill switch. PRGN-3005 UltraCAR-T is under evaluation in a Phase 1b clinical trial (clinical trial identifier: NCT03907527) for the treatment of patients with advanced, recurrent platinum-resistant ovarian cancer. 

 

·Program Status: Enrollment was completed in the Phase 1 dose escalation cohorts of the intraperitoneal (IP) and intravenous (IV) arms without lymphodepletion as well as in the lymphodepletion cohort in the IV arm. Patient follow up is ongoing and the Company expects Phase 1 data to be presented in the first half of 2023. The first patient received a repeat PRGN-3005 dose via IV infusion, following FDA clearance to incorporate repeat dosing in the study protocol. Enrollment is ongoing in the Phase 1b expansion study of PRGN-3005 UltraCAR-T at Dose Level 3 with lymphodepletion prior to IV infusion. Site activation activities are in progress at multiple major cancer centers in the US. Phase 1b clinical trial data presentation is expected in 2024.

 

PRGN-3007 Next Generation UltraCAR-T® with Intrinsic PD-1 Inhibition

 

·Overview: PRGN-3007, based on the next generation of the UltraCAR-T platform, is an investigational multigenic, autologous CAR-T cell therapy engineered to simultaneously express a CAR targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), mbIL15, a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene expression. ROR1 is aberrantly expressed in multiple hematological tumors, including chronic lymphocytic leukemia (CLL), mantle cell leukemia (MCL), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL) and solid tumors, including breast adenocarcinomas such as triple negative breast cancer (TNBC), pancreatic cancer, ovarian cancer, and lung adenocarcinoma. ROR1 is minimally expressed in healthy adult tissues. 

 

·Program Status: Precigen presented an abstract titled, “A Phase1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies,” at ASH. Tech transfer was completed for initiation of the Phase 1 umbrella trial in ROR1+ hematological (CLL, MCL, ALL, DLBCL) and solid tumors (TNBC). The trial is currently open for enrollment and the Company expects to dose the first patient in the first quarter of 2023.

 

Precigen's J.P. Morgan presentation is available on the Company website in the Events & Presentations section.

 

###

 

 

 

Precigen: Advancing Medicine with Precision™

 

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube.

 

UltraCAR-T®

 

UltraCAR-T is a multigenic autologous CAR-T platform that utilizes Precigen's advanced non-viral Sleeping Beauty system to simultaneously express an antigen-specific CAR to specifically target tumor cells, mbIL15 for enhanced in vivo expansion and persistence, and a kill switch to conditionally eliminate CAR-T cells for a potentially improved safety profile. Precigen has advanced the UltraCAR-T platform to address the inhibitory tumor microenvironment by incorporating a novel mechanism for intrinsic checkpoint blockade without the need for complex and expensive gene editing techniques. UltraCAR-T investigational therapies are manufactured via Precigen's overnight manufacturing process using the proprietary UltraPorator® electroporation system at the medical center and administered to patients only one day following gene transfer. The overnight UltraCAR-T manufacturing process does not use viral vectors and does not require ex vivo activation and expansion of T cells, potentially addressing major limitations of current T cell therapies.

 

AdenoVerse™ Immunotherapy

 

Precigen's AdenoVerse immunotherapy platform utilizes a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens designed to modulate the immune system. Precigen's gorilla adenovectors, part of the AdenoVerse library, have potentially superior performance characteristics as compared to current competition. AdenoVerse immunotherapies have been shown to generate high-level and durable antigen-specific neutralizing antibodies and effector T cell immune responses as well as an ability to boost these antibody and T cell responses via repeat administration. Superior performance characteristics and high yield manufacturing of AdenoVerse vectors combined with UltraVector® technology allows Precigen to engineer cutting-edge investigational gene therapies to treat complex diseases.

 

UltraPorator®

 

The UltraPorator system is an exclusive device and proprietary software solution for the scale-up of rapid and cost-effective manufacturing of UltraCAR-T therapies and potentially represents a major advancement over current electroporation devices by significantly reducing the processing time and contamination risk. The UltraPorator device is a high-throughput, semi-closed electroporation system for modifying T cells using Precigen's proprietary non-viral gene transfer technology. UltraPorator is being utilized for clinical manufacturing of Precigen's investigational UltraCAR-T therapies in compliance with current good manufacturing practices.

 

Trademarks

 

Precigen, UltraCAR-T, UltraPorator, AdenoVerse and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

 

Cautionary Statement Regarding Forward-Looking Statements

 

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors“ in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

 

Investor Contact:

Steven M. Harasym 

Vice President, Investor Relations

Tel: +1 (301) 556-9850 

investors@precigen.com

 

Media Contacts:

Donelle M. Gregory 

press@precigen.com

 

Glenn Silver

Lazar-FINN Partners 

glenn.silver@finnpartners.com

 

 

 GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 7 image_002.jpg GRAPHIC begin 644 image_002.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 11, 2023
Entity File Number 001-36042
Entity Registrant Name PRECIGEN, INC.
Entity Central Index Key 0001356090
Entity Tax Identification Number 26-0084895
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 20374 Seneca Meadows Parkway
Entity Address, City or Town Germantown
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20876
City Area Code 301
Local Phone Number 556-9900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, No Par Value
Trading Symbol PGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 dp186955_8k_htm.xml IDEA: XBRL DOCUMENT 0001356090 2023-01-11 2023-01-11 iso4217:USD shares iso4217:USD shares 0001356090 false NASDAQ 8-K 2023-01-11 PRECIGEN, INC. VA 001-36042 26-0084895 20374 Seneca Meadows Parkway Germantown MD 20876 301 556-9900 false false false false Common Stock, No Par Value PGEN false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://precigen.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - dp186955_8k.htm 21 dp186955_8k.htm dp186955_ex9901.htm pgen-20230111.xsd pgen-20230111_lab.xml pgen-20230111_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dp186955_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "dp186955_8k.htm" ] }, "labelLink": { "local": [ "pgen-20230111_lab.xml" ] }, "presentationLink": { "local": [ "pgen-20230111_pre.xml" ] }, "schema": { "local": [ "pgen-20230111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PGEN", "nsuri": "http://precigen.com/20230111", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "dp186955_8k.htm", "contextRef": "From2023-01-11to2023-01-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://precigen.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "dp186955_8k.htm", "contextRef": "From2023-01-11to2023-01-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://precigen.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0000950103-23-000404-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950103-23-000404-xbrl.zip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end